Dr. Karen H. Albritton
Claim this profileCook Children's Medical Center
Studies Lymphoma
Studies Hodgkin's Lymphoma
7 reported clinical trials
19 drugs studied
Area of expertise
1Lymphoma
Stage I
Stage II
CRLF2 positive
2Hodgkin's Lymphoma
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Karen H. Albritton is currently running
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy vs. standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Liposomal Irinotecan-Based Therapy
for Rhabdomyosarcoma
This is a phase I-II study to determine safety and efficacy of combining liposomal irinotecan with vincristine alternating with VAC in intermediate-risk patients, liposomal irinotecan with temozolomide and vincristine alternating with VAC in high-risk patients and the chemotherapy combinations when given with concomitant radiation therapy in intermediate and high risk patients. Primary Objective * The primary objective of the Phase I part is to estimate the maximum tolerated doses (MTDs) and recommended Phase II doses (RP2Ds) of combining liposomal irinotecan with vincristine alternating with VAC in intermediate-risk patients, liposomal irinotecan with temozolomide and vincristine alternating with VAC in high-risk patients and the chemotherapy combinations when given with concomitant radiation therapy in intermediate and high risk patients. * Estimate event-free survival for intermediate-risk participants treated with VAC and vincristine and liposomal irinotecan (VLI) with the addition of maintenance therapy with vinorelbine and cyclophosphamide. * Estimate the event-free survival for high-risk patients treated with VAC and vincristine, liposomal irinotecan, and temozolomide with the addition of maintenance therapy with vinorelbine and cyclophosphamide. * Estimate the local recurrence rate for unresected intermediate- and high-risk patients with initial tumor size with ≥5 cm randomized to between 59.4 GyRBE and 68 GyRBE total proton radiation dose while receiving VAC/VLI (intermediate-risk) or VAC/VLI plus temozolomide (high-risk) and maintenance therapy. Secondary Objectives * To assess the relation between pharmacogenetic variation in CEP72 genotype and vinca alkaloid (vincristine; vinorelbine) disposition in children with rhabdomyosarcoma. * To assess the relation between the pharmacogenetic variation in drug metabolizing enzymes and drug transporters, and the pharmacokinetics of vinca alkaloids, liposomal irinotecan, and cyclophosphamide in children with rhabdomyosarcoma. * To assess the extent of inter-patient variability in the pharmacokinetics of vinca alkaloids, liposomal irinotecan, and cyclophosphamide in children with rhabdomyosarcoma, and explore possible associations between drug disposition and patient specific covariates (e.g., age, sex, race, weight). * Estimate the cumulative incidence of local recurrence in patients with low-risk disease treated with either no adjuvant radiation or minimal volume radiation.
Recruiting1 award Phase 1 & 240 criteria
More about Karen H. Albritton
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Karen H. Albritton has experience with
- Cyclophosphamide
- Vinorelbine
- Ramucirumab
- Brentuximab Vedotin
- Nivolumab
- Vincristine
Breakdown of trials Karen H. Albritton has run
Lymphoma
Hodgkin's Lymphoma
Rhabdomyosarcoma
Sarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Karen H. Albritton specialize in?
Karen H. Albritton focuses on Lymphoma and Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved Stage I patients, or patients who are Stage II.
Is Karen H. Albritton currently recruiting for clinical trials?
Yes, Karen H. Albritton is currently recruiting for 4 clinical trials in Fort Worth Texas. If you're interested in participating, you should apply.
Are there any treatments that Karen H. Albritton has studied deeply?
Yes, Karen H. Albritton has studied treatments such as Cyclophosphamide, Vinorelbine, Ramucirumab.
What is the best way to schedule an appointment with Karen H. Albritton?
Apply for one of the trials that Karen H. Albritton is conducting.
What is the office address of Karen H. Albritton?
The office of Karen H. Albritton is located at: Cook Children's Medical Center, Fort Worth, Texas 76104-2796 United States. This is the address for their practice at the Cook Children's Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.